Shin Nippon Biomedical Laboratories, Ltd.

TSE:2395 Rapporto sulle azioni

Cap. di mercato: JP¥62.3b

Shin Nippon Biomedical Laboratories Gestione

Gestione criteri di controllo 2/4

Shin Nippon Biomedical Laboratories Il CEO è Ryoichi Nagata, nominato in Jan1991, ha un mandato di 33.83 anni. possiede direttamente 2.46% delle azioni della società, per un valore di ¥ 1.53B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 9.4 anni.

Informazioni chiave

Ryoichi Nagata

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO33.8yrs
Proprietà del CEO2.5%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione9.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Sep 19
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Aug 06
Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 26
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 12
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21
Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10
Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12
Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27
Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

AMMINISTRATORE DELEGATO

Ryoichi Nagata (66 yo)

33.8yrs

Mandato

JP¥144,061,000

Compensazione

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Ryoichi Nagata
President33.8yrsJP¥144.06m2.46%
¥ 1.5b
Fumihiko Makino
Senior Executive Officer2.8yrsNessun datoNessun dato
Toshiyuki Iwata
Managing Executive Officerno dataNessun datoNessun dato
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director2.4yrsNessun datoNessun dato
Kyomi Nagatoshi
Senior Managing Executive Officerno dataNessun datoNessun dato
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director20.4yrsNessun dato0.090%
¥ 56.0m
Satoshi Matsumoto
Managing Executive Officer & GM of Fisheries Divisionless than a yearNessun datoNessun dato
Hideshi Tsusaki
Senior MD1.8yrsNessun datoNessun dato
Terumasa Hirai
Managing Executive Officer & President and Representative Director of SNBL Ina Research Centerno dataNessun datoNessun dato
Shu-Ichi Kanazashi
Managing Executive Officerless than a yearNessun datoNessun dato
Eishi Tsunozaki
Senior MD & Directorno dataNessun dato0.043%
¥ 27.1m
Ichiro Nagata
Executive VPno dataNessun dato40.32%
¥ 25.1b

2.4yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di 2395 è considerato esperto (durata media dell'incarico 2.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Ryoichi Nagata
President41.6yrsJP¥144.06m2.46%
¥ 1.5b
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director14.4yrsNessun datoNessun dato
Kyomi Nagatoshi
Senior Managing Executive Officerno dataNessun datoNessun dato
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director21.9yrsNessun dato0.090%
¥ 56.0m
Hideshi Tsusaki
Senior MD10.4yrsNessun datoNessun dato
Eishi Tsunozaki
Senior MD & Director10.4yrsNessun dato0.043%
¥ 27.1m
Ichiro Nagata
Executive VP4.4yrsNessun dato40.32%
¥ 25.1b
Shinichi Fukumoto
Independent Outside Director9.4yrsNessun dato0.00096%
¥ 598.3k
Takashi Yamashita
Independent Outside Director9.4yrsNessun dato0.00096%
¥ 598.3k
Tsuyoshi Hanada
Independent Outside Director4.4yrsNessun dato0.0098%
¥ 6.1m
Keiko Totani
Independent Outside Director3.4yrsNessun dato0.0019%
¥ 1.2m
Chizuru Horishita
Independent Outside Directorless than a yearNessun datoNessun dato

9.4yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2395 sono considerati esperti (durata media dell'incarico 9.4 anni).